Baseline Demographic and Clinicopathologic Characteristics Affecting Treatment Efficacy in Metastatic NSCLC
Nadiye Sever1, Emin Yunusov2, Abdussamet Çelebi1, Nargiz Majidova1, Erkam Kocaaslan1, Pınar Erel1, Yeşim Agyol1, Ali Kaan Güren1, Selver Isik1, Rukiye Arikan1, Osman Köstek1, Murat Sari1, İbrahim Vedat Bayoğlu11Division of Medical Oncology, Department of Internal Medicine, Marmara University Hospital, İstanbul, Türkiye, 2Department of Internal Medicine, Marmara University Hospital, İstanbul, Türkiye
Objectives: We investigated the effects of demographic characteristics and clinicopathologic factors on survival in patients with metastatic non-small cell lung cancer (mNSCLC). Methods: We enrolled 320 patients treated for mNSCLC between January 2012 and December 2023. Progression free survival (PFS) and overall survival (OS) were evaluated. Univariate and multivariate analysis were performed for all pa rameters for prognostic evaluation. Results: Among 320 patients; median age was 63 years. Either presence of bone metastasis (p=0.005), brain metastasis (p=0.024), liver metastasis (p=0.08) and the number of metastasis is 3 or more (p=0.02) were associated with better PFS in univariate analysis. ECOG performance status 0-1 (p=0.001), de novo metastatic disease (p=0.05), bone metastasis (p=0.001), brain metastasis (p=0.016), liver metastasis (p=0.00), also the number of metastasis 3 or more (p=0.001) and use of immu notherapy (p=0.00) were related with longer OS. In multivariate analysis, either presence of brain metastasis (HR:1.50, 95% CI:1.13-1.99, p=0.004), liver metastasis (HR: 1.53, 95% CI: 1.06-2.21, p=0.02), number of metastatic site (HR:0.72, 95% CI: 0.54 0.97, p=0.03) and use of immunotherapy (HR:0.37, 95 % CI: 0.26-0.52, p=0.00) remained significant predictors of OS. Conclusion: Our results showed that liver and brain metastasis, number of metastatic site and use of immunotherapy were assosiated with survival and these can be used as stratification factors when designing randomized clinical trials. Keywords: Survival, metastatic NSCLC, chemotherapy, immunotherapy
Cite This Article
Sever N, Yunusov E, Çelebi A, Majidova N, Kocaaslan E, Erel P, Agyol Y, Güren A, Isik S, Arikan R, Köstek O, Sari M, Bayoğlu İ. Baseline Demographic and Clinicopathologic Characteristics Affecting Treatment Efficacy in Metastatic NSCLC. EJMI. 2024; 8(3): 157-163
Corresponding Author: Nadiye Sever